Stay updated on Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page

  1. Check
    3 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    The page revision was updated from v3.6.0 to v3.6.3. This reflects a minor update to the page metadata rather than the study content.
    Difference
    0.0%
    Check dated 2026-06-30T00:49:51.000Z thumbnail image
  3. Check
    17 days ago
    No Change Detected
  4. Check
    24 days ago
    Change Detected
    Summary
    The page now indicates the trial is no longer recruiting and adds user guidance sections (How to Read a Study Record, Common Questions, How to Join a Study). The Intervention/Treatment heading formatting is adjusted and the revision note updated from v3.5.5 to v3.6.0.
    Difference
    0.3%
    Check dated 2026-06-15T19:06:07.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    New revision history entries were added for 2026-06-01 and 2026-05-28 with Revision: v3.5.5, and older revision entries (2026-05-26, 2026-05-27) along with Revision: v3.5.4 were removed.
    Difference
    0.1%
    Check dated 2026-06-08T14:48:29.000Z thumbnail image
  6. Check
    39 days ago
    Change Detected
    Summary
    Adds update-date entries (2026-05-27, 2026-05-26, 2026-05) and removes the Recruitment status and study contact details from the page, reducing visibility of current enrollment and direct contact options for potential participants.
    Difference
    4%
    Check dated 2026-06-01T05:19:59.000Z thumbnail image
  7. Check
    53 days ago
    Change Detected
    Summary
    The page now shows the study as Active, not recruiting; it adds widened ILD/history exclusions and specifies contraception durations for R-Dx-d as 150 days during treatment and 210 days after the last dose.
    Difference
    0.6%
    Check dated 2026-05-18T03:48:48.000Z thumbnail image
  8. Check
    75 days ago
    Change Detected
    Summary
    ClinicalTrials.gov’s page software revision label was updated from v3.5.2 to v3.5.3, indicating a minor platform/version maintenance change.
    Difference
    0.0%
    Check dated 2026-04-26T08:24:45.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page.